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Neonatal hyperbilirubinaemia necessitating exchange transfusion due to 
maternal sickle cell crisis  
ABSTRACT  
Background: Pregnancy in women with sickle cell disease is associated with a 
number of fetal complications such as intra-uterine death, intra-uterine growth 
restriction (IUGR), preterm birth, low birth weight and an increased perinatal 
mortality and morbidity. Hyperbilirubinemia necessitating exchange transfusion in 
an infant of a mother with sickle cell disease, to our knowledge, has not been 
previously described.  
Highlights: An infant was delivered at 33 weeks and 5 days of gestation due to a 
maternal sickle cell crisis. The infant had an unconjugated bilirubin level of 153 
micromols/L on admission to the neonatal intensive care unit at 30 minutes of age. 
Phototherapy was immediately commenced, intravenous immunoglobulin 
administered and then a double-volume exchange transfusion performed. There 
was, however, no evidence of haemolysis in the infant and the infant’s 
haemoglobin level remained stable following the exchange. No further exchange 
transfusions were required. The mother had a high unconjugated bilirubin level 
(151 micromols/L) prior to delivery. 
Conclusion:  High neonatal unconjugated bilirubin levels necessitating exchange 
transfusion can occur due to haemolysis in the maternal circulation, in this case 
due to sickle cell disease.   






LIST OF ABBREVIATIONS 
IUGR Intra-uterine growth restriction  
LBW Low birth weight  




Severe unconjugated hyperbilirubinemia can result in kernicterus which can result 
in sensorineural hearing loss, dystonia and athetoid cerebral palsy.  Mothers with 
sickle cell disease (SCD) who have an acute sickle cell crisis suffer haemolysis 
resulting in an increase in unconjugated bilirubin levels.  Unconjugated bilirubin 
can transfer across placenta from the maternal to fetal circulation and vice versa, 
whereas it has been demonstrated in animal models, very little conjugated 
bilirubin is able to cross the placenta [1, 2].   Maternal bilirubin levels at delivery 
are comparable post-partum neonatal bilirubin levels as reported in infants born to 
mothers with Crigler Najjar Syndrome. Affected infants have been reported to 
require an exchange transfusion for severe hyperbilirubinemia. 
    
Sickle cell disease is an autosomal recessive haemoglobinopathy and is one of the 
most common monogenic inherited disorders in the world.  Pregnant women with 
sickle cell disease are at an increased risk of having obstetric and sickle related 
complications. Pregnant women suffer more painful crises both pre and post-
partum [3], with an increased risk of anaemia, pre-eclampsia and eclampsia [4]. 
Acute sickle cell pain is common, occurring in between 7 and 25% of pregnancies 
[3]. There is a higher risk of stillbirth, intra-uterine growth restriction (IUGR), low 
birth weight (LBW) and premature delivery, the latter being significantly affected 
by sickle related events in pregnancy [5]. A systematic review of sixteen studies in 
pregnancy outcomes of women with SCD in low or high income countries was 
undertaken [6]. SCD was associated with intrauterine growth retardation odds ratio 
(OR) 2.79, 95% confidence intervals (CI) 1.85-4.21), perinatal mortality (OR 3.76, 
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95% CI 2.34-6.06) and low birth weight (OR 2.00, 95% CI 1.42-2.83).  It was 
associated with an increased risk of pre-eclampsia (OR 2.05, 95% CI 1.83-65.11) 
and eclampsia (OR 3.02, 95% CI 1.20 – 7.58) [6]. 
We report an infant who required an exchange transfusion for severe unconjugated 
hyperbilirubinemia resulting from maternal haemolysis due to a sickle cell crisis.  
 
CASE PRESENATION  
A premature infant was born at 33 weeks and five days of gestation with a 
birthweight of 1980 grams (twenty-fifth centile for weight) to a primigravida 
mother with sickle cell disease (HbSS). All the ultrasound examinations of the fetus 
and Doppler-studies were normal, there was no evidence of fetal growth 
restriction. Throughout the pregnancy she had a baseline haemoglobin of 70gm/L. 
The mother also had glucose-6-phosphate dehydrogenase (G6PD) deficiency. She 
has had one episode of painful crisis at 15 weeks of gestation needing hospital 
admission. She had a further sickle cell crisis at 32 weeks of gestation and required 
an exchange transfusion, following which she developed atypical antibodies. 
 
The infant was delivered at 33 weeks and five days of gestational age by caesarean 
section for maternal reasons, that is on-going sickle cell crisis and sepsis. The 
mother received intravenous immunoglobulin at delivery, her unconjugated 
bilirubin level then was 151 micromols/L. At 30 minutes of age, the infant’s 
bilirubin level was 153 micromols/L. The infant was, therefore, immediately 
started on triple phototherapy and was given intravenous immunoglobulin by three 
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hours of age, based on the National Institute of Clinical excellence (NICE) 
guidelines for exchange transfusion [7]. A double volume exchange transfusion was 
performed at five hours of age which reduced the bilirubin level to 110 
micromols/L. The packed cell volume before the exchange transfusion was 41.8%.  
The blood group of the infant was A positive, the maternal blood group was A 
positive and the Direct Antiglobulin Test (DAT) was negative. Phototherapy was 
continued for another 48 hours during which time there was no rebound rise in the 
bilirubin level. The magnetic resonance imaging scan of the brain performed at 
term showed no evidence of bilirubin encephalopathy. The blood cultures taken 
immediately after birth were negative.   
 
DISCUSSION 
We report an infant who required an exchange transfusion, but had no ongoing 
morbidities due to jaundice. The mother had SCD and we suggest that the neonatal 
hyperbilirubinaemia was due to maternal haemolysis resulting in an elevated 
bilirubin level in the maternal circulation immediately prior to delivery.  Our 
theory is supported by the lack of other causes of early neonatal jaundice and, 
following the exchange transfusion, there was no increase in bilirubin levels.  
 
Approximately 100-200 women with SCD become pregnant each year in the UK [3]. 
Pregnant women with SCD experience increased morbidity mainly due to sickle 
related crises and in fewer cases due to venous thromboembolism, infection and 
chronic end organ dysfunction. The processes contributing to increased maternal 
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complications are pregnancy induced hypertension (PIH), painful crises, 
antepartum haemorrhage, eclampsia, placenta praevia and pulmonary problems; 
there is also an increased maternal mortality. Complications are more common in 
women with an HbSS rather than a HbSC phenotype. In our report, the mother had 
HbSS phenotype and was anaemic during the pregnancy. Women with SCD are six 
times more likely to deliver prematurely than the general population [4] and there 
is also higher incidence of caesarean delivery in pregnant women with SCD. In this 
case, the infant was born prematurely at 33 weeks and five days of gestation by an 
emergency caesarean section for maternal sickle crisis and suspected sepsis. 
Mothers with SCD are more likely to give birth to infants who have suffered 
intrauterine growth retardation (IUGR), partly due to underlying hypertension and 
placental insufficiency [6].   Growth restriction in utero also results from sickling 
and vaso-occlusion in the placental circulation, with increased blood viscosity 
affecting perfusion of the placenta and a reduced oxygen content in the blood due 
to chronic maternal anaemia.  The infant currently presented was delivered 
prematurely and their birth weight was on the twenty-fifth percentile for length.  
The infant was noted to be jaundiced soon after birth with an unconjugated 
bilirubin level of 153 micromols/L at 30 minutes of age, which reflected the 
maternal unconjugated bilirubin level. The fetal liver has low uridine-diphosphate 
glucuronosyltransferase 1A1 enzyme activity and hence the fetus is dependent on 
transfer of unconjugated bilirubin across the placenta into maternal circulation 
where it is converted to conjugated bilirubin and excreted by the maternal liver. 
The transfer of bilirubin from the fetal to the maternal circulation occurs by 
passive diffusion as well as carrier mediated transfer. Bilirubin glucuronides do not 
9 
 
cross the placenta whereas, in contrast, unconjugated bilirubin is readily 
transferred from mother to the fetus in maternal conditions such as Criigler-Najjar 
Sydrome. Previous reports have shown almost similar plasma concentrations of 
unconjugated bilirubin in the infant and mother.   
 
Prolonged bilirubin exposure of the fetus can occur in mothers with Criigler Najjar 
syndrome. The fetus is more susceptible to neurotoxicity from high levels of 
unconjugated bilirubin due to the lower binding affinity of α-fetoprotein to 
unconjugated bilirubin than adults [8].  The adverse outcome can be prevented by 
daily phototherapy with or without semi-monthly albumin transfusions in Criigler 
Najjar type 1 and phenobarbitone administration in mothers with Criigler Najjar 
type 2. In pregnant women with SCD, no specific interventions to reduce bilirubin 
have been reported, except for the management of an acute episode of sickle 
crisis to reduce haemolysis and further bilirubin production.  
One study reported that 77.2% of infants born to mothers who had SS phenotype 
had neonatal jaundice, that is a two to three times higher risk of neonatal 
jaundice when compared to SCD infants born to mothers with a non SS phenotype 
[9]. The haemoglobin phenotype of infants born with SCD did not increase the 
adverse birth outcomes and was comparable to the infants born without SCD, but 
the maternal phenotype was a strong risk factor for adverse outcomes. In contrast, 
in a case control study of infants with SCD, each were matched with two neonates 
without SCD born in the same year.  The SCD infants did not show increased rates 
of jaundice compared to those mothers without SCD [10]. The mother of our infant 
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had HbSS and complications during pregnancy which resulted in an elevated 
unconjugated bilirubin level.  
Magnetic resonance imaging of the brain did not demonstrate the infant described 
had suffered kernicterus.  Nevertheless, a spectrum of minor neurological 
manifestations, consistent with neuroanatomical reports and collectively termed 
as a “syndrome of bilirubin-induced neurologic dysfunction (BIND) can occur in the 
absence of classical kernicterus [1].  Those abnormalities occurred in the following 
domains: neuromotor signs, muscle tone abnormalities, hyperexcitable neonatal 
reflexes, neurobehavioural manifestations, speech and language abnormalities and 
sensorineural audiology and visuomotor dysfunctions [1].  These may manifest from 
neonatal age to childhood. Hence, our patient requires careful follow up.     
In conclusion, neonatal hyperbilirubinaemia necessitating an exchange transfusion 
can occur in an infant of a mother with HbSS disease.  Women with SCD need to be 
aware of this possible complication and unconjugated bilirubin levels need to be 
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